Please login to the form below

Not currently logged in
Email:
Password:

schizophrenia

This page shows the latest schizophrenia news and features for those working in and with pharma, biotech and healthcare.

Alkermes’ new antipsychotic clears FDA advisory committee hurdle

Alkermes’ new antipsychotic clears FDA advisory committee hurdle

Alkermes’ experimental antipsychotic for schizophrenia and bipolar I disorder ALKS 3831 has cleared an US Food and Drug Administration (FDA) expert advisory committee review. ... The favourable outcome of today's joint advisory committee meeting

Latest news

More from news
Approximately 29 fully matching, plus 235 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    year. We’re talking about the lawsuits J&J is facing claiming damages as a result of using its products, including opioid painkillers, Baby Powder talc and its schizophrenia drug Risperdal

  • As the opioid crisis grabs the headlines, the search for safe treatments continues As the opioid crisis grabs the headlines, the search for safe treatments continues

    for opioid addiction, and the long-acting injectable Perseris for schizophrenia in adults, which got FDA approval this year. ... of other drugs that can make it difficult for schizophrenia patients to trust and adhere to regimes.

  • A new era of smart pharma A new era of smart pharma

    According to a systematic review of 39 studies, published in Clinical Psychology in 2002, a mean rate of medication non-adherence in schizophrenia sufferers is 41%, one of the highest of ... Furthermore, given the serious negative effects of

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    Rates of adherence are especially low among patients with chronic conditions such as COPD (33%), schizophrenia (52%) and asthma (67%). ... 80% in just five disease areas - asthma, type 2 diabetes, coronary heart disease, hypertension and schizophrenia -

  • Digital disruption Digital disruption

    Starting with projects in schizophrenia and Parkinson’s disease, Lundbeck and IBM will also work together to identify potential new drug targets and alternative indications.

More from intelligence
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics